We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Merck Wins Approval for First-of-Kind Insomnia Drug

Merck Wins Approval for First-of-Kind Insomnia Drug

August 22, 2014

The FDA has approved Merck’s Belsomra, a new type of sleeping pill for adults who have difficulty falling asleep and/or staying asleep.

The drug is the first sleep aid to work on receptors of the neurotransmitter orexin, which helps keep people awake. In three clinical trials involving some 500 patients, those taking Belsomra (suvorexant) fell asleep faster and spent less time awake during the night than patients on placebo.

The approval includes four dosage strengths — 5 mg, 10 mg, 15 mg and 20 mg — with the recommended dosage being 10 mg within 30 minutes of going to bed. Patients should only use Belsomra if they plan to sleep for at least seven hours, the FDA says. Maximum dosage per day is set at 20 mg.

The approval comes with a caution about unintended drowsiness. A separate study, conducted at the FDA’s request, found that both men and women who took a 20 mg dose of Belsomra experienced some driving impairment the following day.

The FDA has recommended that Belsomra be classified as Schedule IV, Merck says. A final decision by the Drug Enforcement Administration is expected later this year. The company plans to launch Belsomra in the U.S. late this year or in early 2015.

The green light comes approximately one year after the FDA expressed concern over higher doses of the drug and asked Merck to set the starting dose at 10 mg, with a 5 mg option for patients on other therapies that might interfere with Belsomra. At the time, Merck said it would likely have to perform a manufacturing study to assess its capability to produce a stable drug at 5 mg and 10 mg.

Merck spokeswoman Pam Eisele said that the company spent the last year completing those studies and resubmitted its application to the FDA this past February. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing